Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease

Full text
Author(s):
Orestes V. Forlenza [1] ; Breno S. Diniz [1, 2] ; Antonio L. Teixeira [3, 4] ; Florindo Stella [1, 5] ; Wagner Gattaz [1]
Total Authors: 5
Affiliation:
[1] Univ Sao Paulo, Sch Med, Dept & Inst Psychiat, Lab Neurosci LIM 27, BR-05403010 Sao Paulo - Brazil
[2] Univ Fed Minas Gerais, Sch Med, Dept Mental Hlth, Belo Horizonte, MG - Brazil
[3] Univ Fed Minas Gerais, Inst Biol Sci, Lab Immunopharmacol, Neuroimmunol Grp, Belo Horizonte, MG - Brazil
[4] Univ Fed Minas Gerais, Sch Med, Dept Internal Med, Belo Horizonte, MG - Brazil
[5] Univ Estadual Paulista, Biosci Inst, Rio Claro, SP - Argentina
Total Affiliations: 5
Document type: Journal article
Source: Revista Brasileira de Psiquiatria; v. 35, n. 3, p. 284-294, 2013-09-00.
Abstract

Objective: To present a critical review of publications reporting on the rationale and clinical implications of the use of biomarkers for the early diagnosis of Alzheimer's disease (AD). Methods: We conducted a systematic search of the PubMed and Web of Science electronic databases, limited to articles published in English between 1999 and 2012, and based on the following terms: mild cognitive impairment, Alzheimer's disease OR dementia, biomarkers. We retrieved 1,130 articles, of which 175 were reviews. Overall, 955 original articles were eligible. Results: The following points were considered relevant for the present review: a) rationale for biomarkers research in AD and mild cognitive impairment (MCI); b) usefulness of distinct biomarkers for the diagnosis and prediction of AD; c) the role of multimodality biomarkers for the diagnosis and prediction of AD; d) the role of biomarkers in clinical trials of patients with AD and MCI; and e) current limitations to the widespread use of biomarkers in research and clinical settings. Conclusion: Different biomarkers are useful for the early diagnosis and prediction of AD in at-risk subjects. Nonetheless, important methodological limitations need to be overcome for widespread use of biomarkers in research and clinical settings. (AU)

FAPESP's process: 09/52825-8 - Neurobiology of Alzheimer's disease: risk markers, prognosis and therapeutic response
Grantee:Wagner Farid Gattaz
Support Opportunities: Research Projects - Thematic Grants